Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties via hydration.

Question: Cystic fibrosis (CF) is characterised by the accumulation of viscous adherent mucus in the lungs. While several hypotheses invoke a direct relationship with cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction ( i.e. acidic airway surface liquid (ASL) pH, low bicarbonate (HCO ₃ ^- ) concentration, airway dehydration), the dominant biochemical alteration of CF mucus remains unknown.
Materials/methods: We characterised a novel cell line (CFTR-KO Calu3 cells) and the responses of human bronchial epithelial (HBE) cells from subjects with G551D or F508del mutations to ivacaftor and elexacaftor-tezacaftor-ivacaftor. A spectrum of assays such as short-circuit currents, quantitative PCR, ASL pH, Western blotting, light scattering/refractometry (size-exclusion chromatography with inline multi-angle light scattering), scanning electron microscopy, percentage solids and particle tracking were performed to determine the impact of CFTR function on mucus properties.
Results: Loss of CFTR function in Calu3 cells resulted in ASL pH acidification and mucus hyperconcentration (dehydration). Modulation of CFTR in CF HBE cells did not affect ASL pH or mucin mRNA expression, but decreased mucus concentration, relaxed mucus network ultrastructure and improved mucus transport. In contrast with modulator-treated cells, a large fraction of airway mucins remained attached to naïve CF cells following short apical washes, as revealed by the use of reducing agents to remove residual mucus from the cell surfaces. Extended hydration, but not buffers alkalised with sodium hydroxide or HCO ₃ ^- , normalised mucus recovery to modulator-treated cell levels.
Conclusion: These results indicate that airway dehydration, not acidic pH and/or low [HCO ₃ ^- ], is responsible for abnormal mucus properties in CF airways and CFTR modulation predominantly restores normal mucin entanglement.
Competing Interests: Conflict of interest: C.B. Morrison has nothing to disclose. Conflict of interest: K.M. Shaffer has nothing to disclose. Conflict of interest: K.C. Araba has nothing to disclose. Conflict of interest: M.R. Markovetz has nothing to disclose. Conflict of interest: J.A. Wykoff has nothing to disclose. Conflict of interest: N.L. Quinney has nothing to disclose. Conflict of interest: S. Hao has nothing to disclose. Conflict of interest: M.F. Delion has nothing to disclose. Conflict of interest: A.L. Flen has nothing to disclose. Conflict of interest: L.C. Morton has nothing to disclose. Conflict of interest: J. Liao has nothing to disclose. Conflict of interest: D.B. Hill has nothing to disclose. Conflict of interest: M.L. Drumm has nothing to disclose. Conflict of interest: W.K. O'Neal has nothing to disclose. Conflict of interest: M. Kesimer has nothing to disclose. Conflict of interest: M. Gentzsch has nothing to disclose. Conflict of interest: C. Ehre has nothing to disclose.
(Copyright ©The authors 2022. For reproduction rights and permissions contact permissions@ersnet.org.)